Enhancing Monoclonal Antibody Production with BIONET’s F0-BABY Bioreactor
Published July 30, 2025 · By Biogentek Editorial
In the fast-moving world of biopharmaceutical manufacturing, the need for high-quality monoclonal antibodies is greater than ever. This article highlights how BIONET’s F0-BABY bioreactor system is redefining Trastuzumab production using Chinese Hamster Ovary (CHO) cells.
Understanding Trastuzumab’s Role in Cancer Therapy
Trastuzumab (Herceptin) is a revolutionary monoclonal antibody that targets HER2-positive breast cancer. Its production requires advanced bioprocessing systems that ensure stability, purity, and high yield.
Why CHO Cells Lead in Therapeutic Protein Production
CHO cells are widely used due to their adaptability, low viral contamination risk, and excellent protein expression capabilities. Over 70% of therapeutic proteins are produced using CHO systems.
The BIONET F0-BABY Advantage
Developed in Spain, BIONET’s F0-BABY bioreactor offers R&D labs a compact but powerful platform for small-scale manufacturing of monoclonal antibodies.
Key Performance Metrics:
- 16% higher specific growth rate in exponential phase
- 54% better viability at 120 hours
- 2.6× higher antibody concentration in fed-batch mode
- 3× improvement in productivity
- 72% higher specific productivity per cell per day
Advanced Technology Features
- ROSITA® software for full process control & visualization
- Advanced Gas Module supporting up to 5 gas lines
- Fed-batch precision feeding with Variable Speed Pump
- Real-time monitoring (pH, DO, temperature, foam)
- Modular add-ons like bSCALE, bBREATH, and bCPM
Let’s Redefine Your Bioprocessing Strategy
Get access to cutting-edge European bioprocessing technology through Biogentek’s expert support in India.
Talk to Our Team